Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020

Abstract

In this cross-sectional study, pharmaceutical funding was associated with greater odds that an oncology drug would be found to be cost-effective. These findings suggest that simply disclosing potential conflict of interest is inadequate. We encourage cost-effectiveness analyses by independent groups.